R. Wolk - Clin Sci, Pfizer Inc | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 23 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

066 Incidence rates and prevalence of hospital-treated alopecia areata in Denmark (1995-2016)

P. George, U. Heide-Jørgensen, O. Jagun, L. Napatalung,R. Wolk, S. Zwillich, V. Ehrenstein

Journal of Investigative Dermatology（2022）

引用0浏览0引用

Clinical efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) and patients' perception of improvement in alopecia areata: Results from the ALLEGRO Phase 2b/3 trial

E. Guttman-Yassky,T. Ito,A. Jabbari, J. Mackay-Wiggan, A. Lejeune,R. Wolk, D. Wajsbrot, S. H. Zwillich

EXPERIMENTAL DERMATOLOGY（2021）

引用0浏览0引用

托法替布在慢性斑块型银屑病中的获益风险特征

B.E. Strober, A.B. Gottlieb, P.C.M. Kerkhof,L. Puig, H. Bachelez, E. Chouela, S. Imafuku, D. Thaçi, H. Tan,H. Valdez, P. Gupta, M. Kaur,

British Journal of Dermatologyno. 1 (2019)

引用0浏览0引用

Tofacitinib benefit-risk profile in chronic plaque psoriasis

B.E. Strober, A.B. Gottlieb, P.C.M. van de Kerkhof,L. Puig,H. Bachelez,E. Chouela,S. Imafuku, D. Thaçi,H. Tan,H. Valdez,P. Gupta,M. Kaur,

British Journal of Dermatology（2019）

引用0浏览0引用

Benefit-Risk Profile Of Tofacitinib In Patients With Moderate-To-Severe Chronic Plaque Psoriasis: Pooled Analysis Across Six Clinical Trials

B E Strober, A B Gottlieb,P C M van de Kerkhof,L Puig,H Bachelez, E Chouela,S Imafuku,D Thaçi,H Tan,H Valdez,P Gupta, M Kaur,

BRITISH JOURNAL OF DERMATOLOGY（2019）

引用32浏览0WOS引用

THU0299 An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies

D.D. Gladman,Christina Charles-Schoeman,Iain B. McInnes,D.J. Veale,B. Thiers,D. Graham,Cunshan Wang,T.V. Jones,R. Wolk,Ryan DeMasi

ANNALS OF THE RHEUMATIC DISEASES（2018）

引用1浏览0引用

Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis (vol 74, pg AB244, 2016)

H. Tan,H. Valdez,C. Griffiths,U. Mrowietz,A. M. Tallman,R. Wolk,K. B. Gordon

JOURNAL OF DERMATOLOGICAL TREATMENT（2017）

引用0浏览0引用

Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis

T Checchio,S Ahadieh,P Gupta, J Mandema,L Puig,R Wolk,H Valdez,H Tan,S Krishnaswami, A Tallman,M Kaur,K Ito

CLINICAL PHARMACOLOGY & THERAPEUTICSno. 6 (2017): 1006-1016

引用24浏览0WOS引用

Evaluating Dosage Optimality For Tofacitinib, An Oral Janus Kinase Inhibitor, In Plaque Psoriasis, And The Influence Of Body Weight

M. M. Hutmacher, K. Papp, S. Krishnaswami,K. Ito,H. Tan,R. Wolk,H. Valdez, C. Mebus, S. T. Rottinghaus,P. Gupta

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY（2017）

引用13浏览0WOS引用

A MODEL BASED META-ANALYSIS (MBMA) FOR COMPARATIVE EFFICACY OF PSORIASIS TREATMENTS: DOSE-RESPONSE MODEL FOR PSORIASIS AREA AND SEVERITY INDEX (PASI) RESPONSES

T. Checchio,K. Ito,J. Mandema,R. Wolk,H. Valdez,H. Tan, S. Krishnaswami, A. Tallman,P. Gupta

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2016): S44-S45

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn